ArticleJournal of medical genetics2024

Comment to: Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study-determination of immunogenicity.

Malte Lenders et al.PubMed ↗Publisher ↗

No numbers read from the abstract.